 A University of Georgia-based startup is launching a nasal COVID vaccine trial this fall. Sarah Lee Kessler reports. CyanVac LLC has received funding from Project NextGen, a federal initiative based in the U.S. Department of Health and Human Services. The new vaccine, well, that's based on a viral delivery platform containing modified strains of canine influenza.